FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 674 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... April 18, 2025 Virtual Reality Found to Benefit Cancer Patients’ Mental Health October 15, 2021 Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... December 9, 2020 Man Who Lost Wife to Breast Cancer Wants to Donate Her... June 5, 2021 Load more HOT NEWS 3…2…1…Countdown to Medicare Open Enrollment A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with... EMA Recommends Granting a Marketing Authorisation for Nirogacestat How could proposed changes to data protection laws affect research?
